 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
2 News |  |
- tamrintamab pamozirine (SC-003) / AbbVie
SC003 - Tough Cases/controversies in Stroke Neurocritical Care (Stroke Central, Learning Studio 2, Hall C, Booth 647) - Feb 22, 2022 - Abstract #ISC2022ISC_1573;
This will be a Case Discussion educational program with 2 discussants per case and a moderator. Each case will be 20 minutes total with various issues presented and then a 20 minute networking session.
- | tamrintamab pamozirine (SC-003) / AbbVie
Journal: Structure of human DPEP3 in complex with the SC-003 antibody Fab fragment reveals basis for lack of dipeptidase activity. (Pubmed Central) - Aug 4, 2021
P1a/1b
Hence DPEP3, unlike DPEP1 and DPEP2, may require an activating co-factor in vivo or may remain an inactive, degenerate enzyme. This report sheds light on the structural discriminants between active and inactive membrane dipeptidases and provides a benchmark to characterize current and future DPEP3-targeted therapeutic approaches.
- || tamrintamab pamozirine (SC-003) / AbbVie
Clinical, P1 data, Journal, PD(L)-1 Biomarker, IO biomarker: Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. (Pubmed Central) - Apr 16, 2021
P1a/1b
This report sheds light on the structural discriminants between active and inactive membrane dipeptidases and provides a benchmark to characterize current and future DPEP3-targeted therapeutic approaches. SC-003 lacked the requisite safety profile and antitumor activity to warrant further development.
- ||| SC-003 / AbbVie
SC-003 in ovarian cancer. #gyncsm https://t.co/Qppy8ZpT85 (Twitter) - Sep 7, 2020
- |||| budigalimab (ABBV-181) / AbbVie, tamrintamab pamozirine (SC-003) / AbbVie
Trial completion date, Trial termination, Trial primary completion date, Combination therapy: Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer (clinicaltrials.gov) - Jan 4, 2019
P1a/1b, N=74, Terminated, Sponsor: Stemcentrx
SC-003 lacked the requisite safety profile and antitumor activity to warrant further development. Trial completion date: Jan 2020 --> Jan 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2020 --> Jan 2019; Strategic Considerations
- || budigalimab (ABBV-181) / AbbVie, tamrintamab pamozirine (SC-003) / AbbVie
Enrollment closed, Enrollment change, Combination therapy: Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer (clinicaltrials.gov) - Dec 3, 2018
P1a/1b, N=74, Active, not recruiting, Sponsor: Stemcentrx
Trial completion date: Jan 2020 --> Jan 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2020 --> Jan 2019; Strategic Considerations Recruiting --> Active, not recruiting | N=108 --> 74
- || budigalimab (ABBV-181) / AbbVie, tamrintamab pamozirine (SC-003) / AbbVie
Phase classification, Trial primary completion date, Combination therapy: Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer (clinicaltrials.gov) - Jun 28, 2016
P1a/1b, N=108, Recruiting, Sponsor: Stemcentrx
Recruiting --> Active, not recruiting | N=108 --> 74 Phase classification: P1 --> P1a/1b | Trial primary completion date: Jan 2017 --> Jan 2020
- ||| budigalimab (ABBV-181) / AbbVie, tamrintamab pamozirine (SC-003) / AbbVie
New P1 trial, Combination therapy: Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer (clinicaltrials.gov) - Sep 3, 2015
P1, N=108, Recruiting, Sponsor: Stemcentrx